Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma (Q36684500)

15 August 2017

1 reference

title

Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma (English)

1 reference

15 August 2017

Edgardo S Santos

1

1 reference

15 August 2017

Mohamed A Kharfan-Dabaja

series ordinal

2

1 reference

15 August 2017

Ernesto Ayala

series ordinal

3

1 reference

15 August 2017

Luis E Raez

series ordinal

4

1 reference

15 August 2017

publication date

1 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

47

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

2453-2476

1 reference

Follicular lymphoma: a model of lymphoid tumor progression in man.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Radioimmunotherapy of lymphoma: a UC Davis experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Future trends in radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Radiosensitizing nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600923140

10.1080/10428190600923140

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference